CN103140486B - Ccr3-抑制剂的共结晶体及盐 - Google Patents
Ccr3-抑制剂的共结晶体及盐 Download PDFInfo
- Publication number
- CN103140486B CN103140486B CN201180047995.1A CN201180047995A CN103140486B CN 103140486 B CN103140486 B CN 103140486B CN 201180047995 A CN201180047995 A CN 201180047995A CN 103140486 B CN103140486 B CN 103140486B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- acid
- salt
- crystal
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(cc(CN(CC1)CCC1N([C@](CC1)C(Nc2cc(C(N(C)C)=*)cc(C)n2)=O)C1=O)cc1)c1Cl Chemical compound Cc(cc(CN(CC1)CCC1N([C@](CC1)C(Nc2cc(C(N(C)C)=*)cc(C)n2)=O)C1=O)cc1)c1Cl 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186901 | 2010-10-07 | ||
EP10186901.4 | 2010-10-07 | ||
PCT/EP2011/067437 WO2012045803A1 (en) | 2010-10-07 | 2011-10-06 | Co-crystals and salts of ccr3-inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103140486A CN103140486A (zh) | 2013-06-05 |
CN103140486B true CN103140486B (zh) | 2016-08-03 |
Family
ID=44741339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180047995.1A Active CN103140486B (zh) | 2010-10-07 | 2011-10-06 | Ccr3-抑制剂的共结晶体及盐 |
Country Status (36)
Country | Link |
---|---|
US (3) | US8742115B2 (zh) |
EP (1) | EP2625174B1 (zh) |
JP (1) | JP5794713B2 (zh) |
KR (3) | KR102163874B1 (zh) |
CN (1) | CN103140486B (zh) |
AP (1) | AP3268A (zh) |
AR (1) | AR083353A1 (zh) |
AU (1) | AU2011311530B2 (zh) |
BR (2) | BR122021010665B1 (zh) |
CA (1) | CA2807255C (zh) |
CL (1) | CL2013000488A1 (zh) |
CO (1) | CO6710910A2 (zh) |
CY (1) | CY1116168T1 (zh) |
DK (1) | DK2625174T3 (zh) |
EA (1) | EA029097B1 (zh) |
EC (1) | ECSP13012600A (zh) |
ES (1) | ES2535264T3 (zh) |
GE (1) | GEP20166488B (zh) |
HR (1) | HRP20150419T1 (zh) |
HU (1) | HUE024540T2 (zh) |
IL (1) | IL224269A (zh) |
MA (1) | MA34545B1 (zh) |
ME (1) | ME02040B (zh) |
MX (1) | MX2013003785A (zh) |
MY (1) | MY167898A (zh) |
NZ (1) | NZ605827A (zh) |
PE (1) | PE20140188A1 (zh) |
PL (1) | PL2625174T3 (zh) |
PT (1) | PT2625174E (zh) |
RS (1) | RS53858B1 (zh) |
SG (1) | SG188949A1 (zh) |
SI (1) | SI2625174T1 (zh) |
TW (1) | TWI546294B (zh) |
UA (1) | UA109290C2 (zh) |
UY (1) | UY33655A (zh) |
WO (1) | WO2012045803A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
AR090566A1 (es) * | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
US20200054622A1 (en) * | 2017-04-05 | 2020-02-20 | Alkahest, Inc. | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors |
KR20190131078A (ko) * | 2017-04-05 | 2019-11-25 | 알카헤스트 인코포레이티드 | Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 |
AU2018248425B2 (en) | 2017-04-05 | 2024-03-28 | Alkahest Inc. | Methods and compositions for treating retina-associated disease using CCR3-inhibitors |
AU2018347447B2 (en) * | 2017-10-13 | 2024-03-07 | Alkahest, Inc. | Methods and compositions for treating pruritus, xerosis, and associated disease using CCR3-inhibitors |
CA3097083A1 (en) | 2018-05-15 | 2019-11-21 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
BR112021004938A2 (pt) * | 2018-09-26 | 2021-06-01 | Alkahest, Inc. | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 |
AU2021287906A1 (en) * | 2020-06-11 | 2022-12-15 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102388032A (zh) * | 2009-04-08 | 2012-03-21 | 贝林格尔.英格海姆国际有限公司 | 作为ccr3拮抗剂的取代的哌啶 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7907121L (sv) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
AU2335699A (en) | 1998-01-21 | 1999-08-09 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
AU2654399A (en) | 1998-02-02 | 1999-08-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
CA2467555A1 (en) | 2001-11-29 | 2003-08-14 | Schering Corporation | Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections |
EP1596869B1 (en) * | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Novel cocrystallization |
MXPA06004304A (es) | 2003-10-24 | 2006-06-05 | Hoffmann La Roche | Antagonistas del receptor ccr-3. |
JP2007520556A (ja) | 2004-02-05 | 2007-07-26 | シェーリング コーポレイション | Ccr3アンタゴニストとして有用なピペリジン誘導体 |
WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
JP2006137718A (ja) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
CA2647448A1 (en) * | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
AU2007242883B2 (en) | 2006-04-20 | 2012-09-27 | F. Hoffmann-La Roche Ag | Diazepan derivatives modulators of chemokine receptors |
GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2011
- 2011-06-10 UA UAA201305572A patent/UA109290C2/ru unknown
- 2011-10-06 EA EA201300436A patent/EA029097B1/ru unknown
- 2011-10-06 PL PL11764572T patent/PL2625174T3/pl unknown
- 2011-10-06 GE GEAP201113082A patent/GEP20166488B/en unknown
- 2011-10-06 KR KR1020177037823A patent/KR102163874B1/ko active IP Right Grant
- 2011-10-06 JP JP2013532190A patent/JP5794713B2/ja active Active
- 2011-10-06 US US13/267,417 patent/US8742115B2/en active Active
- 2011-10-06 UY UY0001033655A patent/UY33655A/es unknown
- 2011-10-06 ME MEP-2015-17A patent/ME02040B/me unknown
- 2011-10-06 KR KR1020137008683A patent/KR101844215B1/ko active IP Right Grant
- 2011-10-06 ES ES11764572.1T patent/ES2535264T3/es active Active
- 2011-10-06 WO PCT/EP2011/067437 patent/WO2012045803A1/en active Application Filing
- 2011-10-06 AU AU2011311530A patent/AU2011311530B2/en active Active
- 2011-10-06 DK DK11764572.1T patent/DK2625174T3/da active
- 2011-10-06 HU HUE11764572A patent/HUE024540T2/hu unknown
- 2011-10-06 EP EP11764572.1A patent/EP2625174B1/en active Active
- 2011-10-06 MY MYPI2013000801A patent/MY167898A/en unknown
- 2011-10-06 MA MA35770A patent/MA34545B1/fr unknown
- 2011-10-06 MX MX2013003785A patent/MX2013003785A/es active IP Right Grant
- 2011-10-06 RS RS20150131A patent/RS53858B1/en unknown
- 2011-10-06 CN CN201180047995.1A patent/CN103140486B/zh active Active
- 2011-10-06 PE PE2013000781A patent/PE20140188A1/es not_active Application Discontinuation
- 2011-10-06 KR KR1020197025850A patent/KR102239690B1/ko active IP Right Grant
- 2011-10-06 BR BR122021010665-7A patent/BR122021010665B1/pt active IP Right Grant
- 2011-10-06 AR ARP110103717A patent/AR083353A1/es unknown
- 2011-10-06 BR BR112013008211-9A patent/BR112013008211B1/pt active IP Right Grant
- 2011-10-06 CA CA2807255A patent/CA2807255C/en active Active
- 2011-10-06 AP AP2013006679A patent/AP3268A/xx active
- 2011-10-06 NZ NZ605827A patent/NZ605827A/en unknown
- 2011-10-06 SG SG2013013305A patent/SG188949A1/en unknown
- 2011-10-06 PT PT11764572T patent/PT2625174E/pt unknown
- 2011-10-06 SI SI201130394T patent/SI2625174T1/sl unknown
- 2011-10-06 TW TW100136338A patent/TWI546294B/zh active
-
2013
- 2013-01-17 IL IL224269A patent/IL224269A/en unknown
- 2013-02-19 CL CL2013000488A patent/CL2013000488A1/es unknown
- 2013-04-08 CO CO13090552A patent/CO6710910A2/es unknown
- 2013-05-03 EC ECSP13012600 patent/ECSP13012600A/es unknown
-
2014
- 2014-01-22 US US14/160,646 patent/US20140135307A1/en not_active Abandoned
- 2014-12-17 US US14/572,889 patent/US9233950B2/en active Active
-
2015
- 2015-04-07 CY CY20151100331T patent/CY1116168T1/el unknown
- 2015-04-15 HR HRP20150419TT patent/HRP20150419T1/hr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102388032A (zh) * | 2009-04-08 | 2012-03-21 | 贝林格尔.英格海姆国际有限公司 | 作为ccr3拮抗剂的取代的哌啶 |
Non-Patent Citations (1)
Title |
---|
The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists;Pauline C. Ting, et al;《Bioorganic & Medicinal Chemistry Letters》;20051231;第15卷;1375-1378 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103140486B (zh) | Ccr3-抑制剂的共结晶体及盐 | |
CN102388032B (zh) | 作为ccr3拮抗剂的取代的哌啶 | |
DE60218511T2 (de) | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase | |
CN1759114B (zh) | 作为细胞因子抑制剂的杂环n-芳基甲酰胺 | |
CN1993327B (zh) | 3-氨基甲酰基-2-吡啶酮衍生物 | |
TW200524934A (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
CN101115740A (zh) | 作为代谢调节剂的经取代吡啶基和嘧啶基衍生物和相关疾病的治疗 | |
CN103974950A (zh) | 作为ccr(4)拮抗剂的取代的苯并咪唑类和苯并吡唑类 | |
CN102317265B (zh) | 用于治疗炎性疾病的2,4-嘧啶二胺化合物 | |
CN101679254A (zh) | 用于炎症治疗的哌啶酮类 | |
TW200409630A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
JPH11510159A (ja) | 抗けいれん剤としての未置換および置換n−(ピロール−1−イル)ピリジンアミンの使用 | |
OA16358A (en) | Co-crystals and salts of CCR3-inhibitors. | |
OA16376A (en) | Modular storage and handling device for a plurality of flexible pipes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1181381 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170329 Address after: American California Patentee after: Evergreen springs Address before: In Germany Patentee before: Boehringer Ingelheim Int |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1181381 Country of ref document: HK |